<DOC>
	<DOCNO>NCT00025519</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . Sometimes transplanted cell reject body 's tissue . Mycophenolate mofetil , tacrolimus , donor white blood cell may prevent happen . PURPOSE : Phase II trial study effectiveness chemotherapy follow peripheral stem cell transplantation treat patient metastatic recurrent kidney cancer .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Treating Patients With Metastatic Recurrent Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility submyeloablative HLA-identical allogeneic peripheral blood stem cell transplantation patient metastatic recurrent renal cell carcinoma . - Determine toxicity regimen , term incidence severity graft rejection , acute graft-vs-host disease ( GVHD ) , chronic GVHD , adverse effect preparative regimen thalidomide , infection bleeding , patient . - Determine efficacy regimen , term objective partial complete response rate , patient . - Determine engraftment rate extent chimerism patient treat regimen . - Determine overall survival time treatment failure rate patient treat regimen . - Determine impact thalidomide treatment chronic GVHD patient treat regimen . OUTLINE : Patients stratify accord risk ( low vs high ) . Patients receive fludarabine IV 30 minute daily day -4 -2 follow total body irradiation day -1 . Patients receive tacrolimus IV 24 hour orally daily day -3 35 oral mycophenolate mofetil twice daily day -3 28 graft-vs-host disease ( GVHD ) prophylaxis . Patients undergo allogeneic peripheral blood stem cell transplantation 1-2 hour day 0 . Patients maintain mixed chimerism evidence grade III IV GVHD receive donor lymphocyte infusion ( DLI ) day 60 , 90 , 120 . Patients may receive additional DLI need . Patients limit chronic GVHD receive oral thalidomide daily begin day 80 continue 1 year disease progression resolution chronic GVHD . Patients follow 1 , 3 , 6 , 12 month every 6 month thereafter . PROJECTED ACCRUAL : A maximum 20-40 patient ( 10-20 per stratum ) accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma ( RCC ) Histology demonstrate major clear cell component Metastatic ( stage IV ) recurrent disease Prior debulking nephrectomy required Disease amenable complete surgical resection Must HLAidentical donor Matched relate sibling donor must 6/6 serologic HLA A , B , DR match molecular confirmation DRB1 A 5/6 serologic mismatch one antigen mismatch locus A B ( DR ) molecular confirmation locus A , B , DRB1 allow Matched unrelated donor must minimum 8 10 molecular match loci A , B , C , DRB1 , DQB1 No brain metastasis Negative MRI require PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Karnofsky 80100 % OR ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) ALT/AST le 2 time ULN Alkaline phosphatase less 2 time ULN Hepatitis A , B , C negative Renal : Creatinine clearance great 50 mL/min Calcium le 10.5 mg/dL ( bisphosphonates allow ) Cardiovascular : LVEF le 10 % low limit normal Pulmonary : FEV_1 DLCO great 50 % Other : HIV negative No active bacterial , fungal , viral ( include cytomegalovirus ) infections No intolerance allergy tacrolimus , mycophenolate mofetil , fludarabine No intolerance 200 cGy total body irradiation No serious comorbid disease , neurologic condition , psychosocial condition would preclude study followup Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 month , , least 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interleukin2 allow Prior interferon alfa allow Chemotherapy : Prior chemotherapy allow No concurrent chemotherapy RCC Endocrine therapy : No concurrent corticosteroids comorbid disease Radiotherapy : No prior extensive radiotherapy marrow microenvironment great 20 % total marrow mass No prior radiotherapy reach tissue tolerance heart , lung , liver , kidney , spinal cord Surgery : See Disease Characteristics Other : No concurrent therapy RCC No concurrent enrollment another investigational protocol treatment RCC No concurrent immunosuppressive medication No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>